143 related articles for article (PubMed ID: 18334011)
21. Rosiglitazone, a Peroxisome Proliferator-Activated Receptor (PPAR)-γ Agonist, Attenuates Inflammation Via NF-κB Inhibition in Lipopolysaccharide-Induced Peritonitis.
Zhang YF; Zou XL; Wu J; Yu XQ; Yang X
Inflammation; 2015 Dec; 38(6):2105-15. PubMed ID: 26047949
[TBL] [Abstract][Full Text] [Related]
22. Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model.
Carta AR; Frau L; Pisanu A; Wardas J; Spiga S; Carboni E
Neuroscience; 2011 Oct; 194():250-61. PubMed ID: 21839812
[TBL] [Abstract][Full Text] [Related]
23. Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-γ by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions.
Nenicu A; Körbel C; Gu Y; Menger MD; Laschke MW
Hum Reprod; 2014 May; 29(5):1011-24. PubMed ID: 24578472
[TBL] [Abstract][Full Text] [Related]
24. In-vivo antioxidant and anti-inflammatory activity of rosiglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonists in animal model of bronchial asthma.
El-Naa MM; El-Refaei MF; Nasif WA; Abduljawad SH; El-Brairy AI; El-Readi MZ
J Pharm Pharmacol; 2015 Oct; 67(10):1421-30. PubMed ID: 26099551
[TBL] [Abstract][Full Text] [Related]
25. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial.
Grey A; Bolland M; Gamble G; Wattie D; Horne A; Davidson J; Reid IR
J Clin Endocrinol Metab; 2007 Apr; 92(4):1305-10. PubMed ID: 17264176
[TBL] [Abstract][Full Text] [Related]
26. Apoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats.
Weissgarten J; Berman S; Efrati S; Rapoport M; Averbukh Z; Feldman L
Nephrol Dial Transplant; 2006 May; 21(5):1198-204. PubMed ID: 16449288
[TBL] [Abstract][Full Text] [Related]
27. Rosiglitazone and PPAR-gamma overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family proteins.
Wu JS; Lin TN; Wu KK
J Cell Physiol; 2009 Jul; 220(1):58-71. PubMed ID: 19229877
[TBL] [Abstract][Full Text] [Related]
28. Rosiglitazone enhances 5-fluorouracil-induced cell growth inhibition in hepatocellular carcinoma cell line Hep3B.
Cao LQ; Shao ZL; Peng HP; Xiao JB; Xia T
Chin J Cancer; 2010 Aug; 29(8):741-6. PubMed ID: 20663321
[TBL] [Abstract][Full Text] [Related]
29. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats.
Sánchez-Hidalgo M; Martín AR; Villegas I; Alarcón De La Lastra C
Biochem Pharmacol; 2005 Jun; 69(12):1733-44. PubMed ID: 15876425
[TBL] [Abstract][Full Text] [Related]
30. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates acrolein-induced airway mucus hypersecretion in rats.
Liu DS; Liu WJ; Chen L; Ou XM; Wang T; Feng YL; Zhang SF; Xu D; Chen YJ; Wen FQ
Toxicology; 2009 Jun; 260(1-3):112-9. PubMed ID: 19464576
[TBL] [Abstract][Full Text] [Related]
31. Rosiglitazone inhibits insulin-like growth factor‑1-induced polycystic kidney disease cell growth and p70S6 kinase activation.
Liu C; Zhang Y; Yuan L; Fu L; Mei C
Mol Med Rep; 2013 Sep; 8(3):861-4. PubMed ID: 23864113
[TBL] [Abstract][Full Text] [Related]
32. Effect of ligand of peroxisome proliferator-activated receptor gamma on the biological characters of hepatic stellate cells.
Guo YT; Leng XS; Li T; Peng JR; Song SH; Xiong LF; Qin ZZ
World J Gastroenterol; 2005 Aug; 11(30):4735-9. PubMed ID: 16094720
[TBL] [Abstract][Full Text] [Related]
33. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
Moulin D; Bianchi A; Boyault S; Sebillaud S; Koufany M; Francois M; Netter P; Jouzeau JY; Terlain B
Arthritis Rheum; 2005 Mar; 52(3):759-69. PubMed ID: 15751073
[TBL] [Abstract][Full Text] [Related]
34. Resolution of Inflammation by Resolvin D1 Is Essential for Peroxisome Proliferator-activated Receptor-γ-mediated Analgesia during Postincisional Pain Development in Type 2 Diabetes.
Saito T; Hasegawa-Moriyama M; Kurimoto T; Yamada T; Inada E; Kanmura Y
Anesthesiology; 2015 Dec; 123(6):1420-34. PubMed ID: 26492476
[TBL] [Abstract][Full Text] [Related]
35. Rescue of glandular dysmorphogenesis in PTEN-deficient colorectal cancer epithelium by PPARγ-targeted therapy.
Jagan I; Fatehullah A; Deevi RK; Bingham V; Campbell FC
Oncogene; 2013 Mar; 32(10):1305-15. PubMed ID: 22543585
[TBL] [Abstract][Full Text] [Related]
36. Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model.
Demerjian M; Man MQ; Choi EH; Brown BE; Crumrine D; Chang S; Mauro T; Elias PM; Feingold KR
Exp Dermatol; 2006 Mar; 15(3):154-60. PubMed ID: 16480422
[TBL] [Abstract][Full Text] [Related]
37. Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction.
Tao L; Wang Y; Gao E; Zhang H; Yuan Y; Lau WB; Chan L; Koch WJ; Ma XL
Circ Res; 2010 Feb; 106(2):409-17. PubMed ID: 19940263
[TBL] [Abstract][Full Text] [Related]
38. PPAR-γ activation by rosiglitazone suppresses angiotensin II-mediated proliferation and phenotypictransition in cardiac fibroblasts via inhibition of activation of activator protein 1.
Hou X; Zhang Y; Shen YH; Liu T; Song S; Cui L; Bu P
Eur J Pharmacol; 2013 Sep; 715(1-3):196-203. PubMed ID: 23791613
[TBL] [Abstract][Full Text] [Related]
39. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
40. Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3'-kinase-dependent pathway.
Lin CY; Gurlo T; Haataja L; Hsueh WA; Butler PC
J Clin Endocrinol Metab; 2005 Dec; 90(12):6678-86. PubMed ID: 16204373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
